Limb-Girdle Muscular Dystrophy 2B and Miyoshi Presentations of Dysferlinopathy

American Journal of the Medical Sciences

Volumn 353, Issue 5, 2017, Pages 484-491

  Patel, Nirupa J ^a   Van Dyke, Kenneth W ^a   Espinoza, Luis R ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Calpain; Caveolin; Dysferlin; Limb girdle muscular dystrophy 2B; Miyoshi myopathy

Indexed keywords

AMINOTRANSFERASE; CALPAIN; CAVEOLIN; CREATINE KINASE; CREATINE KINASE MM; DYSFERLIN; PREDNISONE;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DYSFERLINOPATHY; FATIGUE; FEMALE; GASTROCNEMIUS MUSCLE; GENE THERAPY; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; IMMUNOHISTOCHEMISTRY; LIMB GIRDLE MUSCULAR DYSTROPHY; MALE; MIYOSHI MYOPATHY; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE TRAINING; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; SARCOLEMMA; DIFFERENTIAL DIAGNOSIS; LOUISIANA; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; PATHOLOGY; YOUNG ADULT;

ADULT; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LOUISIANA; MALE; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; YOUNG ADULT;

EID: 85006070025     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1016/j.amjms.2016.05.024     Document Type: Article

References (45)

1. Park, H., Hong, J., Suh, G., et al. Heterogenous characteristics of Korean patients with dysferlinopathy. Neuroscience 27 (2012), 423–429.
2. Liu, J., Aoki, M., Illa, I., et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 20 (1998), 31–36.
3. Urtizberea, J., Bassez, G., Leturcq, F., et al. Dysferlinopathies. Neurol India 56:3 (2008), 289–297.
4. Moore, S., Shilling, C., Westra, S., et al. Limb-girdle muscular dystrophy in the United States. J Neuropathol Exp Neurol 65 (2007), 995–1003.
5. Argov, Z., Sadeh, M., Mazor, K., et al. Muscular dystrophy due to dysferlin deficiency in Libyan Jews: clinical and genetic features. Brain 123 (2000), 1229–1237.
6. Dugan, E., Huber, A., Miller, F., et al. Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J, 15(2), 2009, 1.
7. Fraser, D., Frank, J., Dalakas, M., et al. Magnetic resonance imaging in the idiopathic inflammatory myopathies. J Rheumatol 18:11 (1991), 1693–1700.
8. Ernste, F., Reed, A., Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc 88:1 (2013), 83–105.
9. Choi, J., Yeong-Eun, P., Kim, S., et al. Differential immunohistological features of inflammatory myopathies and dysferlinopathy. J Korean Med Sci 24 (2009), 1015–1023.
10. Needham, M., Corbett, A., Day, T., et al. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci 15:2 (2008), 1350–1353.
11. Lorenzoni, P., Scola, R., Kay, et al. Idiopathic inflammatory myopathies in childhood: a brief review of 27 cases. Pediatr Neurol 45:1 (2011), 17–22.
12. Baer, A., Differential diagnosis of idiopathic inflammatory myopathies. Curr Rheumatol Rep 8 (2006), 178–187.
13. Emery, A., The muscular dystrophies. Lancet 359 (2002), 687–695.
14. Engelman, J., Zhang, X., Galbiati, F., et al. Molecular genetics of the caveolin gene family: implications for human cancers, diabetes, Alzheimers disease and muscular dystrophy. Am J Hum Genet 63 (1998), 1578–1587.
15. McNally, E., de Sa Moreira, E., Duggan, D., et al. Caveolin-3 in muscular dystrophy. Hum Mol Genet 7 (1998), 871–877.
16. Minetti, C., Sotgia, F., Bruno, C., et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet 18 (1998), 365–368.
17. Song, K., Scherer, P., Tang, Z., et al. Expression of caveolin-3 in skeletal, cardiac, and smooth muscle. The J Biol Chem 271:25 (1996), 15160–15165.
18. Laval, S., Bushby, K., Limb-girdle muscular dystrophies—from genetics to molecular pathology. Neuropathol Appl Neurobiol 30 (2004), 91–105.
19. Richard, I., Broux, O., Allamand, V., et al. Mutations in the proteolytic enzyme, calpain 3, cause limb girdle muscular dystrophy type 2A. Cell 81 (1995), 27–40.
20. Richard, I., Brenguier, L., Dincer, P., et al. Multiple independent molecular etiologies for limb-girdle muscular dystrophy type 2A patients from various geographical origins. Am J Hum Genet 60 (1997), 1128–1138.
21. Richard, I., Roudaut, C., Saenz, A., et al. Calpainopathy—a survey of mutations and polymorphisms. Am J Hum Genet 64 (1999), 1524–1540.
22. Ono, Y., Shimada, H., Sorimachi, H., et al. Functional defects of a muscle-specific calpain, p94, caused by mutations associated with limb-girdle muscular dystrophy type 2A. Biol Chem 273 (1998), 17073–17078.
23. Baghdiguian, S., Martin, M., Richard, I., et al. Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IκBα/NF-κΒ pathway in limb-girdle muscular dystrophy type 2A. Nat Med 5 (1999), 503–511.
24. Fardeau, M., Hillaire, D., Mignard, C., et al. Juvenile limb girdle muscular dystrophy. Clinical histopathological and genetic data from a small community living in the reunion island. Brain 119 (1996), 295–308.
25. Duggan, D., Gorospe, J., Fanin, M., et al. Mutations in the sarcoglycan genes in patients with myopathy. N Engl J Med 336 (1997), 618–624.
26. Bushby, K., Making sense of the limb girdle muscle dystrophies. Brain 122 (1999), 1403–1420.
27. Leung, D., Taylor, H., Lindy, A., et al. A case of progressive quadriceps weakness and elevated creatine kinase level mimicking inclusion body myositis. Arthritis Care Res 66:2 (2014), 328–333.
28. Van Adel, B., Tarnopolsky, M., Metabolic myopathies: update 2009. J Clin Neuromusc Dis 10 (2009), 97–121.
29. Ruff, R., Weissman, J., Endocrine myopathies. Neurol Clin 6:3 (1988), 575–592.
30. Sieb, J., Gillessen, T., Iatrogenic and toxic myopathies. Muscle Nerve 27 (2003), 142–156.
31. Mohassel, P., Mammen, A., Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies. Muscle Nerve 48 (2013), 477–483.
32. Patel, N., Patel, N., Espinoza, L., HIV infection and rheumatic disease: the changing spectrum of clinical enigma. Rheum Dis Clin North Am 35:1 (2009), 139–161.
33. Attarian, S., Azulay, J., Infectious myopathies. Rev Prat 51:3 (2001), 284–288.
34. Mariano, A., Henning, A., Han, R., Dysferlin-deficient muscular dystrophy and innate immune activation. FEBS J 280 (2013), 4165–4176.
35. Han, R., Muscle membrane repair and inflammatory attack in dysferlinopathy. Skelet Muscle, 1, 2011, 10.
36. Klinge, L., Harris, J., Sewry, C., et al. Dysferlin associates with the developing T-tubule system in rodent and human skeletal muscle. Muscle Nerve 42 (2010), 166–173.
37. de Morree, A., Hensbergen, P., van Haagen, H., et al. Proteomic analysis of the dysferlin protein complex unveils its importance for sarcolemmal maintenance and integrity. PLoS One, 5, 2010, e13854.
38. Rawat, R., Cohen, T., Ampong, B., et al. Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle. Am J Pathol 176 (2010), 2891–2900.
39. Hochmeister, S., Grundtner, R., Bauer, J., et al. Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol 65 (2006), 855–865.
40. Nagaraju, K., Rawat, R., Veszelovszky, E., et al. Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. Am J Pathol 172 (2008), 774–785.
41. Han, R., Frett, E., Levy, J., et al. Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice. J Clin Invest 120 (2010), 4366–4374.
42. Linssen, W., Notermans, N., Van der Graaf, Y., et al. Miyoshi-type distal muscular dystrophy: clinical spectrum in 24 Dutch patients. Brain 120 (1997), 1989–1996.
43. Nguyen, K., Bassez, G., Krahn, M., et al. Phenotypic study in 50 patients with dysferlin gene mutations. Arch Neurol 64:8 (2007), 1176–1182.
44. Jethwa, H., Jacques, T., Gunny, R., et al. Limb girdle muscular dystrophy type 2B masquerading as inflammatory myopathy: case report. Pediatr Rheumatol, 11, 2013, 19.
45. Walter, M., Reilich, P., Thiele, S., et al. Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial. Orphanet J Rare Dis, 8, 2013, 26.